Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4

被引:2
|
作者
Jiang, Pin [1 ]
Chen, Tao [2 ]
Chu, Lin-Feng [1 ]
Xu, Ren-Peng [1 ]
Gao, Jin-Ting [3 ]
Wang, Li [3 ]
Liu, Qiang [3 ]
Tang, Lily [3 ]
Wan, Hong [1 ]
Li, Ming [4 ]
Ren, Hong-Can [3 ]
机构
[1] Shanghai Medicilon Inc, Dept DMPK, 585 Chuanda Rd, Shanghai 201299, Peoples R China
[2] Shanghai PharmoGo Co Ltd, Shanghai, Peoples R China
[3] GenFleet Therapeut Shanghai Inc, Drug Discovery Dept, 1206 Zhangjiang Rd, Suite A, Shanghai 201203, Peoples R China
[4] Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, 1 Jianshe Rd, Zhengzhou 450000, Peoples R China
关键词
Drug-drug interaction; PBPK; fraction metabolized; CYP inhibition;
D O I
10.1080/17425255.2023.2263358
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Enhancing the precision of drug-drug interaction (DDI) prediction is essential for improving drug safety and efficacy. The aim is to identify the most effective fraction metabolized by CY3A4 (fm) for improving DDI prediction using physiologically based pharmacokinetic (PBPK) models.Research Design and Methods: The fm values were determined for 33 approved drugs using a human liver microsome for in vitro measurements and the ADMET Predictor software for in silico predictions. Subsequently, these fm values were integrated into PBPK models using the GastroPlus platform. The PBPK models, combined with a ketoconazole model, were utilized to predict AUCR (AUCcombo with ketoconazole/AUCdosing alone), and the accuracy of these predictions was evaluated by comparison with observed AUCR.Results: The integration of in vitro fm method demonstrates superior performance compared to the in silico fm method and fm of 100% method. Under the Guest-limits criteria, the integration of in vitro fm achieves an accuracy of 76%, while the in silico fm and fm of 100% methods achieve accuracies of 67% and 58%, respectively.Conclusions: Our study highlights the importance of in vitro fm data to improve the accuracy of predicting DDIs and demonstrates the promising potential of in silico fm in predicting DDIs.
引用
收藏
页码:721 / 731
页数:11
相关论文
共 50 条
  • [21] Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction
    Chen, Yuan
    Ma, Fang
    Lu, Tong
    Budha, Nageshwar
    Jin, Jin Yan
    Kenny, Jane R.
    Wong, Harvey
    Hop, Cornelis E. C. A.
    Mao, Jialin
    CLINICAL PHARMACOKINETICS, 2016, 55 (06) : 735 - 749
  • [22] Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model
    Yamazaki, Shinji
    Johnson, Theodore R.
    Smith, Bill J.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (10) : 1417 - 1429
  • [23] A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR SIMULATION OF NALOXEGOL PHARMACOKINETICS AND DRUG-DRUG INTERACTION (DDI) POTENTIAL
    Zhou, D.
    Bui, K.
    Sostek, M.
    Al-Huniti, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S53 - S53
  • [24] Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach
    Guangwei Jia
    Congcong Ren
    Hongyan Wang
    Caixia Fan
    BMC Pharmacology and Toxicology, 25
  • [25] Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin
    Miners, John O.
    Pattanawongsa, Attarat
    Rowland, Andrew
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (02) : 392 - 393
  • [26] Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study
    Lang, Jennifer
    Vincent, Ludwig
    Chenel, Marylore
    Ogungbenro, Kayode
    Galetin, Aleksandra
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (06) : 1618 - 1630
  • [27] Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates
    Otsuka, Yukio
    Poondru, Srinivasu
    Bonate, Peter L.
    Rose, Rachel H.
    Jamei, Masoud
    Ushigome, Fumihiko
    Minematsu, Tsuyoshi
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2023, 50 (05) : 365 - 376
  • [28] Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates
    Yukio Otsuka
    Srinivasu Poondru
    Peter L. Bonate
    Rachel H. Rose
    Masoud Jamei
    Fumihiko Ushigome
    Tsuyoshi Minematsu
    Journal of Pharmacokinetics and Pharmacodynamics, 2023, 50 : 365 - 376
  • [29] Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions
    Garcia, Luna Prieto
    Janzen, David
    Kanebratt, Kajsa P.
    Ericsson, Hans
    Lennernas, Hans
    Lundahl, Anna
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (10) : 1420 - 1433
  • [30] CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect
    Boulenc, Xavier
    Nicolas, Olivier
    Hermabessiere, Stephanie
    Zobouyan, Isabelle
    Martin, Valerie
    Donazzolo, Yves
    Ollier, Celine
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2016, 41 (01) : 45 - 54